| APCs | antigen-presenting cells |
| APOBEC | apolipoprotein-B mRNA editing enzyme catalytic polypeptide-like |
| Bcl-xL | B cell lymphoma-extra large |
| bTMB | plasma-based tumor mutational burden |
| cCSCs | circulating cancer stem-like cells |
| CPS | combined positive score |
| CTCs | circulating tumor cells |
| ctDNA | circulating tumor DNA |
| CTLA-4 | cytotoxic T lymphocyte antigen 4 |
| dMMR | mismatch repair deficiency |
| EBV | Epstein-Barr virus |
| EpCAM | Epithelial cell adhesion molecule |
| FDA | Food and Drug Administration |
| GEP | gene expression profile |
| HNSCC | head and neck squamous cell carcinoma |
| HPV | human papillomavirus |
| ICIs | immune checkpoint inhibitors |
| IFN | interferon |
| IS | immunoscore |
| LAG-3 | lymphocyte-activating gene 3 |
| NIH | National Institutes of Health |
| Mb | megabase |
| MSI | microsatellite instability |
| MSI-H | high microsatellite instability |
| NK | natural killer |
| OR | odds ratio |
| OS | overall survival |
| PD-1 | programmed cell death protein-1 |
| PD-L1 | programmed death ligand-1 |
| PFS | progression-free survival |
| R/M HNSCC | recurrent and metastatic HNSCC |
| SCC | Squamous cell carcinoma |
| SOC | standard of care |
| TCGA | The Cancer Genome Atlas |
| TIGIT | T cell immunoreceptor with Ig and ITIM domains |
| TIM-3 | T cell immunoglobulin and mucin domain-containing protein 3 |
| TMB | tumor mutational burden |
| TME | tumor microenvironment |
| TPS | tumor proportion score |
| Tregs | regulatory T cells |